The invention relates to applications of carbazole compound in preparation of drugs or health care food used for treating metabolic diseases and complications of metabolic diseases. The carbazole compound is 3, 6-dibromo-beta-fluorine-N-(3-methoxyphenyl)-9H-carbazole-9-propylanmine (P7C3-A20). It is confirmed through high fat high sugar diet induced hyperlipidemia, obesity, and fatty liver animalmodel experiments that P7C3-A20 is capable reducing blood fat, blood sugar, obesity, and fatty liver lesion obviously; it is confirmed by cardiac muscle cell ischemic anoxic model simulated ischemic myocardial injury that P7C3-A20 is capable of reducing myocardial cell injury caused by ischemia and anoxia. The advantages are that: 1, the carbazole compound is capable of reducing blood fat, blood sugar, obesity, and fatty liver lesion obviously, preventing and treating fatty liver, and avoiding ischemic myocardial injury; and 2, a novel drug research direction is provided for metabolic bone disease and complications of metabolic bone diseases, and the application prospect is promising.